)
Pacira BioSciences (PCRX) investor relations material
Pacira BioSciences 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Business Overview and Strategic Vision
Focused on innovative, non-opioid pain management, helping over 18 million patients and generating $726 million in unaudited 2025 sales with 800+ employees.
Mission centers on delivering transformative pain therapies, guided by patient-centricity, scientific rigor, integrity, and team diversity.
5x30 strategy targets growth and value creation by 2030, focusing on musculoskeletal pain and adjacent markets.
Portfolio includes EXPAREL (flagship nerve block), ZILRETTA (corticosteroid for osteoarthritis), and iovera (cryoneurolysis device).
Achieved 40%+ stock price increase and highest historical margins, driven by manufacturing efficiency and robust commercial organization.
Strategic Initiatives, Partnerships, and Global Expansion
Launched 5x30 strategy: help 3 million patients, double-digit top-line growth, five-point margin expansion, five new pipeline programs, and five partnerships by 2030.
Signed key partnerships with Johnson & Johnson (tripling ZILRETTA reach) and LG Chem (Asia-Pacific commercial rights for EXPAREL and potential ZILRETTA sales), with regulatory filings planned for South Korea and Thailand in 2026.
Acquired GQ Bio, securing the HCAd platform for PCRX-201 and initiated three preclinical programs (dry eye, degenerative disc disease, canine IL-1Ra).
Five partnerships established, supporting global expansion and pipeline advancement.
Settled with Fresenius and Hengrui, extending EXPAREL market visibility to 2039 and expanded IP estate to 21 patents.
Commercial Performance, Market Access, and Adoption
NOPAIN legislation provides separate reimbursement for 11 products, including EXPAREL and iovera, at ASP plus 6 for Medicare outpatients.
Covered lives reached 102 million in 2025, with early uptake in ambulatory surgery centers and smaller hospitals.
Over 90% of EXPAREL business now contracted, supporting steady volume and top-line growth.
Real-world evidence and HEOR data support expanded utilization and formulary wins.
82% of surveyed stakeholders view NOPAIN as important for non-opioid stewardship; 92% believe it reduces opioid prescribing.
Next Pacira BioSciences earnings date
Next Pacira BioSciences earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)